---
title: "Thyroid antibody status, subclinical hypothyroidism, and the…"
description: "Thyroid antibody status does not independently predict coronary heart disease risk in individuals with subclinical hypothyroidism."
url: "https://magellanlongevity.com/study/d24915118.md"
canonical: "https://magellanlongevity.com/study/d24915118.html"
html: "https://magellanlongevity.com/study/d24915118.html"
type: "study"
study_key: "d24915118"
journal: "J Clin Endocrinol Metab"
year: 2014
pmid: "24915118"
doi: "10.1210/jc.2014-1250"
citations: 1
updated: 2026-09-02
author: "Gabriel Radu, DO"
author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765."
publisher: "Magellan Longevity"
content_format: "markdown"
---

# Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease

[Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Thyroid antibody status, subclinical hypothyroidism, and…

**HTML version:** https://magellanlongevity.com/study/d24915118.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d24915118

## Citation

| Field | Value |
| --- | --- |
| Journal | J Clin Endocrinol Metab |
| Year | 2014 |
| PMID | [24915118](https://pubmed.ncbi.nlm.nih.gov/24915118/) |
| DOI | [10.1210/jc.2014-1250](https://doi.org/10.1210/jc.2014-1250) |
| Study key | d24915118 |

## Takeaway

Thyroid antibody status does not independently predict coronary heart disease risk in individuals with subclinical hypothyroidism.

## The question

Does thyroid autoimmunity, specifically the presence of thyroid peroxidase antibodies (TPOAbs), independently affect the risk of coronary heart disease (CHD) in individuals with subclinical hypothyroidism?

## Hypothesis

The study aimed to compare the CHD risk in subclinical hypothyroidism with and without TPOAbs to determine if thyroid autoimmunity independently affects CHD risk.

## Methods

A MEDLINE and EMBASE search from 1950 to 2011 was conducted to identify prospective cohorts reporting baseline thyroid function, antibodies, and CHD outcomes. Individual data from 38,274 participants across six cohorts were analyzed for CHD mortality, and 33,394 participants from four cohorts for CHD events.

## Results

Among 38,274 adults, 1691 (4.4%) had subclinical hypothyroidism, with 775 (45.8%) of these having positive TPOAbs. Compared with euthyroid individuals, age- and gender-adjusted risks of CHD mortality in subclinical hypothyroidism were similar for those with and without TPOAbs (HR 1.15 vs HR 1.26). Similarly, risks of CHD events did not differ by TPOAb status (HR 1.16 vs HR 1.26). Risks of CHD mortality and events increased with higher thyrotropin levels, but within each thyrotropin stratum, risks did not differ by TPOAb status.

## Conclusion

The risk of coronary heart disease associated with subclinical hypothyroidism did not differ based on thyroid peroxidase antibody status. This suggests that biomarkers of thyroid autoimmunity do not provide independent prognostic information for CHD outcomes.

## Limitations

The abstract does not explicitly state any limitations of the study.

## Verbatim from the abstract

> Risks of coronary heart disease mortality and events increased with higher thyrotropin

## Adjusted Hazard Ratios for CHD Mortality and Events in Subclinical Hypothyroidism

| Measure | Hazard Ratio |
| --- | --- |
| CHD Mortality (No TPOAbs) | 1.15 |
| CHD Mortality (Positive TPOAbs) | 1.26 |
| CHD Events (No TPOAbs) | 1.16 |
| CHD Events (Positive TPOAbs) | 1.26 |

*Hazard ratios for CHD mortality and events in individuals with subclinical hypothyroidism, stratified by thyroid peroxidase antibody (TPOAb) status, compared to euthyroid individuals.*

## Where this study is used on Magellan

This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions.

| Compound or device | Evidence grade | Graded pages |
| --- | --- | --- |
| Thyroid (TSH) Home Panel | — | — |

## Reference

1. **Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease**
   J Clin Endocrinol Metab 2014 · [PMID 24915118](https://pubmed.ncbi.nlm.nih.gov/24915118/) · [DOI 10.1210/jc.2014-1250](https://doi.org/10.1210/jc.2014-1250)

   > Risks of coronary heart disease mortality and events increased with higher thyrotropin

## Structured data

```json
{"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d24915118.html#page","url":"https://magellanlongevity.com/study/d24915118.html","name":"Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease","description":"Thyroid antibody status does not independently predict coronary heart disease risk in individuals with subclinical hypothyroidism.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d24915118.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Thyroid antibody status, subclinical hypothyroidism, and…","item":"https://magellanlongevity.com/study/d24915118.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d24915118.html#study","name":"Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease","headline":"Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease","datePublished":"2014","isPartOf":{"@type":"Periodical","name":"J Clin Endocrinol Metab"},"identifier":"PMID:24915118","url":"https://pubmed.ncbi.nlm.nih.gov/24915118/","sameAs":"https://doi.org/10.1210/jc.2014-1250","abstract":"Thyroid antibody status does not independently predict coronary heart disease risk in individuals with subclinical hypothyroidism."}]}
```

## Related on Magellan Longevity

- [Evidence: TSH and thyroid function](https://magellanlongevity.com/study/s148.md)
- [Longevity research map](https://magellanlongevity.com/longevity-research-map.html)
- [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md)

## Scope and disclosures

Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication.

Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases.

Reviewed for accuracy by a board-certified physician (DO).